Bioequivalence studies for three formulations of a recombinant human growth hormone: challenges and lessons learned.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The estimate for relative bioavailability (AUC(0-24 h)) was within the prespecified BE interval (0.80-1.25).

Who Took Part

The study group was 4 subjects.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, men only.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the crossover set-up each of the subjects took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Biological Availability, Human Growth Hormone, Recombinant Proteins and Therapeutic Equivalency.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 4 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2010 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.